Cost-Effectiveness Analysis Using Data from Multinational Trials: The Use of Bivariate Hierarchical Modeling
暂无分享,去创建一个
Nigel Rice | Andrea Manca | Mark Sculpher | Paul C Lambert | M. Sculpher | P. Lambert | A. Manca | N. Rice
[1] J C Wakefield,et al. Hierarchical models for multicentre binary response studies. , 1990, Statistics in medicine.
[2] A. Briggs,et al. Something old, something new, something borrowed, something blue: a framework for the marriage of health econometrics and cost-effectiveness analysis. , 2002, Health economics.
[3] Andrew Gelman,et al. General methods for monitoring convergence of iterative simulations , 1998 .
[4] P A Poole-Wilson,et al. Low doses vs. high doses of the angiotensin converting‐enzyme inhibitor lisinopril in chronic heart failure: a cost‐effectiveness analysis based on the Assessment of Treatment with Lisinopril and Survival (ATLAS) study , 2000, European journal of heart failure.
[5] B. O'brien,et al. Country specific cost comparisons from multinational clinical trials using empirical Bayesian shrinkage estimation: the Canadian ASSENT-3 economic analysis. , 2005, Health economics.
[6] P C Lambert,et al. Analysis of ambulatory blood pressure monitor data using a hierarchical model incorporating restricted cubic splines and heterogeneous within‐subject variances , 2001, Statistics in medicine.
[7] F Follath,et al. [Cost effectiveness of bisoprolol in treatment of heart failure in Germany. An analysis based on the CIBIS-II study]. , 2000, Medizinische Klinik.
[8] S. Fienberg. When did Bayesian inference become "Bayesian"? , 2006 .
[9] R. Grieve,et al. Using multilevel models for assessing the variability of multinational resource use and cost data. , 2005, Health economics.
[10] David J. Spiegelhalter,et al. Bayesian graphical modelling: a case‐study in monitoring health outcomes , 2002 .
[11] David B. Dunson,et al. Bayesian Data Analysis , 2010 .
[12] Richard Grieve,et al. Addressing the issues that arise in analysing multicentre cost data, with application to a multinational study. , 2006, Journal of health economics.
[13] Michael Drummond,et al. Assessing the appropriateness of combining economic data from multinational clinical trials , 2003, Statistics in medicine.
[14] B. Liljas,et al. Cost-effectiveness analysis of a dry powder inhaler (Turbuhaler) versus a pressurised metered dose inhaler in patients with asthma. , 1997, PharmacoEconomics.
[15] T. Lüscher,et al. High Dose Lisinopril in Heart Failure: Economic Considerations , 2002, Cardiovascular Drugs and Therapy.
[16] A O'Hagan,et al. Bayesian cost‐effectiveness analysis from clinical trial data , 2001, Statistics in medicine.
[17] Andrew R Willan,et al. 'Lost in translation': accounting for between-country differences in the analysis of multinational cost-effectiveness data. , 2006, PharmacoEconomics.
[18] A O'Hagan,et al. Bayesian methods for design and analysis of cost-effectiveness trials in the evaluation of health care technologies , 2002, Statistical methods in medical research.
[19] Simon G Thompson,et al. Methods for incorporating covariate adjustment, subgroup analysis and between-centre differences into cost-effectiveness evaluations. , 2005, Health economics.
[20] A. Localio,et al. Adjustments for Center in Multicenter Studies: An Overview , 2001, Annals of Internal Medicine.
[21] J Hutton,et al. Cost effectiveness of eptifibatide in acute coronary syndromes; an economic analysis of Western European patients enrolled in the PURSUIT trial. The Platelet IIa/IIb in unstable Angina: Receptor Suppression Using Integrilin Therapy. , 2002, European heart journal.
[22] M. G. Smith,et al. Clinical and economic benefits of ramipril: an Australian analysis of the HOPE study , 2003, Internal medicine journal.
[23] Jesse A. Berlin,et al. Confounding Due to Cluster in Multicenter Studies—Causes and Cures , 2002, Health Services and Outcomes Research Methodology.
[24] B. O'brien,et al. Cost–effectiveness analysis for multinational clinical trials , 2005, Statistics in medicine.
[25] Lianne Sheppard,et al. Insights on bias and information in group-level studies. , 2003, Biostatistics.
[26] M. Sculpher,et al. Assessing generalisability by location in trial-based cost-effectiveness analysis: the use of multilevel models. , 2005, Health economics.
[27] A A Tsiatis,et al. Cost-effectiveness of platelet glycoprotein IIb/IIIa inhibition with eptifibatide in patients with non-ST-elevation acute coronary syndromes. , 2000, Circulation.
[28] Andrea Manca,et al. Increasing the generalizability of economic evaluations: Recommendations for the design, analysis, and reporting of studies , 2005, International Journal of Technology Assessment in Health Care.
[29] F. Pang,et al. Generalisability in economic evaluation studies in healthcare: a review and case studies. , 2004, Health technology assessment.
[30] Y. R. Wang,et al. High- versus low-dose angiotensin converting enzyme inhibitor therapy in the treatment of heart failure: an economic analysis of the Assessment of Treatment with Lisinopril and Survival (ATLAS) trial. , 2003, The American journal of managed care.
[31] T. Kahan,et al. The cost‐effectiveness of ramipril in the treatment of patients at high risk of cardiovascular events: a Swedish sub‐study to the HOPE study , 2002, Journal of internal medicine.
[32] C. Roberts,et al. The implications of variation in outcome between health professionals for the design and analysis of randomized controlled trials. , 1999, Statistics in medicine.
[33] S. Thompson,et al. How should cost data in pragmatic randomised trials be analysed? , 2000, BMJ : British Medical Journal.
[34] R. Willke,et al. Estimating country-specific cost-effectiveness from multinational clinical trials. , 1998, Health economics.
[35] Ita G. G. Kreft,et al. Multilevel Analysis Methods , 1994 .
[36] S. Pocock,et al. Subgroup analysis, covariate adjustment and baseline comparisons in clinical trial reporting: current practiceand problems , 2002, Statistics in medicine.
[37] M. A. Best. Bayesian Approaches to Clinical Trials and Health‐Care Evaluation , 2005 .
[38] Alex J. Sutton,et al. Methods for Meta-Analysis in Medical Research , 2000 .
[39] J Hjelmgren,et al. Health economic guidelines--similarities, differences and some implications. , 2001, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[40] Ruth Brown,et al. Cost effectiveness in Canada of eptifibatide treatment for acute coronary syndrome patients using PURSUIT subgroup analysis. , 2003, The Canadian journal of cardiology.
[41] A. Gelman. Prior distributions for variance parameters in hierarchical models (comment on article by Browne and Draper) , 2004 .
[42] Andrew R Willan,et al. Regression methods for covariate adjustment and subgroup analysis for non-censored cost-effectiveness data. , 2004, Health economics.
[43] S. Greenland. Ecologic versus individual-level sources of bias in ecologic estimates of contextual health effects. , 2001, International journal of epidemiology.
[44] Harold I Feldman,et al. Individual patient‐ versus group‐level data meta‐regressions for the investigation of treatment effect modifiers: ecological bias rears its ugly head , 2002, Statistics in medicine.
[45] Andrew R Willan,et al. Conducting economic evaluations alongside multinational clinical trials: toward a research consensus. , 2005, American heart journal.
[46] J. Caro,et al. Are the WOSCOPS clinical and economic findings generalizable to other populations? A case study for Belgium. The WOSCOPS Economic Analysis Group. West of Scotland Coronary Prevention Study. , 2000, Acta cardiologica.
[47] Mirjam Moerbeek,et al. A comparison between traditional methods and multilevel regression for the analysis of multicenter intervention studies. , 2003, Journal of clinical epidemiology.
[48] P A Poole-Wilson,et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. , 1999, Circulation.
[49] P. Fletcher,et al. A cost-effectiveness analysis of enalapril maleate in the management of congestive heart failure in Australia. , 1996, Australian and New Zealand journal of medicine.
[50] David R. Jones,et al. How vague is vague? A simulation study of the impact of the use of vague prior distributions in MCMC using WinBUGS , 2005, Statistics in medicine.
[51] R. A. Henderson,et al. The costs of routine eptifibatide use in acute coronary syndromes in Western Europe : an economic substudy of the PURSUIT trial , 1999 .
[52] L. Tavazzi,et al. The role of arrhythmias in the progression of heart failure , 1999, European journal of heart failure.
[53] D. Spiegelhalter,et al. Bayesian Approaches to Clinical Trials and Health-Care Evaluation: Spiegelhalter/Clinical Trials and Health-Care Evaluation , 2004 .
[54] Ron Goeree,et al. Transferability of economic evaluations: approaches and factors to consider when using results from one geographic area for another , 2007, Current medical research and opinion.